Synthetic lethality is the phenomenon that a mutation in gene X or gene Y is viable, whereas inactivation of both X and Y simultaneously is lethal. Recently, the breast cancer susceptibility gene BRCA-2 was found to be synthetic lethal with PARP-1 in human cell cultures and in mice, possibly making PARP a potent and specific drug target for breast cancer in humans (Bryant et al, 2005; Farmer et al, 2005). Using C. elegans, we aim to identify additional synthetic lethal interactions with several tumor suppressor genes, such as
dog-1 (BACH1/FANCJ), Y41E3.9 (FANCD2),
pme-1 (PARP-1),
pme-2 (PARP-2),
cep-1 (
p53) and
atm-1 (ATM). At least two alleles will be used for each gene to prevent nonspecific interactions due to background mutations. These alleles are used in a genome-wide liquid RNAi screen for synthetic lethality, by comparing the presence of offspring in mutant alleles to N2. Positive hits will be further validated and checked for homology in humans.. For this screen, we will isolate new mutant alleles from our EMS library. We use LIMSTILL software (available at
http://limstill.niob.knaw.nl) for amplicon selection, primer design, sequence analysis and mutation annotation, facilitating high-throughput sequencing. Up to 3072 sequences can be processed and aligned simultaneously and can therefore be easily screened for mutations. In addition, we are optimizing a reporter assay for double strand break (DSB) repair. We have developed transgenic animals that carry a reporter LacZ sequence interrupted by the restriction site of the yeast rare-cutting endonuclease I-SceI. Animals also carry a hsp::I-SceI array that allows the introduction of a localized DSB in the LacZ reporter sequence by heatshock treatment. Inadequate repair of the DSB can be detected by LacZ expression or by PCR of the sequence flanking the DSB. This assay can be used to study localized DSB repair and may also be used for genome-wide screens for additional DSB-repair and signaling genes.